Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment
By API User
BEIJING & PRAGUE–BUSINESS WIRE– Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group. The licensing agreement will advance the development of an innovative antibody-drug conjugate (ADC) targeting a novel tumor … Continued